Market Overview

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

Related ENDP
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
US Stock Futures Up Ahead Of Economic Data

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.

In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”

Endo Health Solutions closed on Thursday at $35.96.

Latest Ratings for ENDP

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Oct 2014Cantor FitzgeraldUpgradesSellHold
Sep 2014RBC CapitalInitiates Coverage onOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Corey Davis JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ENDP)

Around the Web, We're Loving...

Get Benzinga's Newsletters